Glenn van Langenhove, MD, PhD for the DELAYED RRISC (Dea
Articles
Late mortality with sirolimus-eluting stents in diseased saphenous vein grafts
Pierfrancesco Agostoni, MD;Paul Vermeersch, MD;Stefan Verheye, MD, PhD;Paul van den Heuvel, MD;Carl Convens, MD;Frank van den Branden, MD;Glenn van Langenhove, MD, PhD for the DELAYED RRISC (Dea
September 5th 2008In a secondary post-hoc analysis of the Reduction of Restenosis in Saphenous Vein Grafts with Cypher (RRISC) trial, we compared the long-term safety of sirolimus-eluting stents (SES) with bare-metal stents (BMS) in diseased saphenous vein grafts
Read More
Latest Updated Articles
Published: May 2nd 2024 | Updated: May 6th 2024
Cardiology Month in Review: April 2024
Published: October 9th 2024 | Updated: October 10th 2024
AHN Welcomes New Physicians
Published: October 5th 2024 | Updated: October 10th 2024
FDA News Month in Review: September 2024
Published: April 30th 2024 | Updated: October 10th 2024
Discussing Risankizumab, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD
Published: October 5th 2024 | Updated: October 10th 2024
Real-World Study Reveals Rimegepant Usage Trends for Acute and Preventive Migraine Treatment
Published: October 9th 2014 | Updated: October 10th 2024
Widespread "Yellow Bumps"
